We aim to do this by leading the field in discovering, developing and delivering impactful precision medicines through unparalleled insight into disease-driving fibroblast subpopulations.
Fibroblasts are a type of cell present in many different tissues in the body; recent data point to them as being important drivers of disease.
Our Founder team are world-leaders in the field and have identified exciting new biology, opening up new therapeutic approaches. Mestag’s team of drug discovery experts is passionate about developing impactful new therapeutics for patients with cancer and inflammatory disease.
We are working on a portfolio of antibody programs and searching for new therapeutic targets using our target discovery engine.
Based in Cambridge UK, Mestag is backed by SV Health Investors and JJDC (Johnson and Johnson Innovation), leading life science & healthcare investors.